Treatment options in Raynaud's phenomenon

Bibliography

• Silman A, Holligan S, Brennan P, et al. Prevalence of symptoms of Raynaud's phenomenon in general practice. BMJ 1990;301(6752):590-2
   PubMedGoogle Scholar
• Herrick AL. The pathogenesis, diagnosis and treatment of Raynaud phenomenon. Nat Rev Rheumatol 2012;8(8):469-79
   PubMed Web of Science ®Google Scholar
• Herrick AL. Pathogenesis of Raynaud's phenomenon. Rheumatology (Oxford) 2005;44(5):587-96
   PubMed Web of Science ®Google Scholar
• Gunawardena H, Harris ND, Carmichael C, et al. Maximum blood flow and microvascular regulatory responses in systemic sclerosis. Rheumatology (Oxford) 2007;46(7):1079-82
   PubMedGoogle Scholar
• Vancheeswaran R, Azam A, Black C, et al. Localization of endothelin-1 and its binding sites in scleroderma skin. J Rheumatol 1994;21(7):1268-76
   PubMedGoogle Scholar
• Pignone A, Rosso AD, Brosnihan KB, et al. Reduced circulating levels of angiotensin-(1–7) in systemic sclerosis: a new pathway in the dysregulation of endothelial-dependent vascular tone control. Ann Rheum Dis 2007;66(10):1305-10
   PubMed Web of Science ®Google Scholar
• Fava A, Wung PK, Wigley FM, et al. Efficacy of Rho kinase inhibitor fasudil in secondary Raynaud's phenomenon. Arthritis Care Res (Hoboken) 2012;64(6):925-9
   PubMedGoogle Scholar
• Flavahan NA, Flavahan S, Liu Q, et al. Increased alpha2-adrenergic constriction of isolated arterioles in diffuse scleroderma. Arthritis Rheum 2000;43(8):1886-90
   PubMedGoogle Scholar
• Bunker CB, Terenghi G, Springall DR, et al. Deficiency of calcitonin gene-related peptide in Raynaud's phenomenon. Lancet 1990;336(8730):1530-3
   PubMedGoogle Scholar
• Susol E, MacGregor AJ, Barrett JH, et al. A two-stage, genome-wide screen for susceptibility loci in primary Raynaud's phenomenon. Arthritis Rheum 2000;43(7):1641-6
   PubMedGoogle Scholar
• Radstake TR, Gorlova O, Rueda B, et al. Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat Genet 2010;42(5):426-9
   PubMed Web of Science ®Google Scholar
• Gorlova O, Martin JE, Rueda B, et al. Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy. PLoS Genet 2011;7(7):e1002178
   Web of Science ®Google Scholar
• Wigley FM. Vascular disease in scleroderma. Clin Rev Allergy Immunol 2009;36:150-75
   PubMedGoogle Scholar
• LeRoy EC, Medsger TA Jr. Raynaud's phenomenon: a proposal for classification. Clin Exp Rheumatol 1992;10(5):485-8
   PubMed Web of Science ®Google Scholar
• LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15(2):202-5
   PubMed Web of Science ®Google Scholar
• den Hoogen F, Khanna D, Fransen J, et al. 2013 Classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis 2013;72(11):1747-55
   PubMedGoogle Scholar
• Ennis H, Vail A, Wragg E, et al. A prospective study of systemic sclerosis-related digital ulcers: prevalence, location, and functional impact. Scand J Rheumatol 2013;42(6):483-6
   PubMed Web of Science ®Google Scholar
• Mouthon L, Mestre-Stanislas C, Bérezné A, et al. Impact of digital ulcers on disability and health-related quality of life in systemic sclerosis. Ann Rheum Dis 2010;69(1):214-17
   PubMed Web of Science ®Google Scholar
• Koenig M, Joyal F, Fritzler MJ, et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum 2008;58(12):3902-12
   PubMed Web of Science ®Google Scholar
• Nihtyanova SI, Denton CP. Autoantibodies as predictive tools in systemic sclerosis. Nat Rev Rheumatol 2010;6(2):112-16
   PubMed Web of Science ®Google Scholar
• Cutolo M, Sulli A, Pizzorni C, et al. Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis. J Rheumatol 2000;27(1):155-60
   PubMed Web of Science ®Google Scholar
• Maricq HR, LeRoy EC. Patterns of finger capillary abnormalities in connective tissue disease by “wide-field” microscopy. Arthritis Rheum 1973;16(5):619-28
   PubMedGoogle Scholar
• Matucci-Cerinic M, Allanore Y, Czirják L, et al. The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research Group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy. Ann Rheum Dis 2009;68(9):1377-80
   PubMed Web of Science ®Google Scholar
• Avouac J, Fransen J, Walker UA, et al. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis 2011;70(3):476-81
   PubMed Web of Science ®Google Scholar
• Smith V, De Keyser F, Pizzorni C, et al. Nailfold capillaroscopy for day-to-day clinical use: construction of a simple scoring modality as a clinical prognostic index for digital trophic lesions. Ann Rheum Dis 2011;70(1):180-3
   PubMed Web of Science ®Google Scholar
• Sebastiani M, Manfredi A, Vukatana G, et al. Predictive role of capillaroscopic skin ulcer risk index in systemic sclerosis: a multicentre validation study. Ann Rheum Dis 2012;71(1):67-70
   PubMed Web of Science ®Google Scholar
• Kowal-Bielecka O, Landewe R, Avouac J, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009;68(5):620-8
   PubMed Web of Science ®Google Scholar
• Thompson AE, Shea B, Welch V, et al. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum 2001;44(8):1841-7
   PubMed Web of Science ®Google Scholar
• Flather MD, Yusuf S, Køber L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000;355(9215):1575-81
   PubMed Web of Science ®Google Scholar
• Madsen JL, Hvidt S. Raynaud's disease treated with captopril (Capoten). A randomized double-blind cross-over study. Ugeskr Laeger 1984;146(36):2695-7
   PubMedGoogle Scholar
• Rustin MH, Almond NE, Beacham JA, et al. The effect of captopril on cutaneous blood flow in patients with primary Raynaud's phenomenon. Br J Dermatol 1987;117(6):751-8
   PubMed Web of Science ®Google Scholar
• Tosi S, Marchesoni A, Messina K, et al. Treatment of Raynaud's phenomenon with captopril. Drugs Exp Clin Res 1987;13(1):37-42
   PubMedGoogle Scholar
• Janini SD, Scott DG, Coppock JS, et al. Enalapril in Raynaud's phenomenon. J Clin Pharm Ther 1988;13(2):145-50
   PubMed Web of Science ®Google Scholar
• Challenor VF, Waller DG, Hayward RA, et al. Subjective and objective assessment of enalapril in primary Raynaud's phenomenon. Br J Clin Pharmacol 1991;31(4):477-80
   PubMedGoogle Scholar
• Gliddon AE, Doré CJ, Black C, et al. Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. Arthritis Rheum 2007;56(11):3837-46
   PubMedGoogle Scholar
• Stewart M, Morling JR. Oral vasodilators for primary Raynaud's phenomenon. Cochrane Database Syst Rev 2012. [Epub ahead of print]
   Google Scholar
• Dziadzio M, Denton CP, Smith R, et al. Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 1999;42(12):2646-55
   PubMedGoogle Scholar
• Kleckner MS Jr, Allen EV, Wakim KG. The effect of local application of glyceryl trinitrate (nitroglycerine) on Raynaud's disease and Raynaud's phenomenon; studies on blood flow and clinical manifestations. Circulation 1951;3(5):681-9
   PubMedGoogle Scholar
• Anderson ME, Moore TL, Hollis S, et al. Digital vascular response to topical glyceryl trinitrate, as measured by laser Doppler imaging, in primary Raynaud's phenomenon and systemic sclerosis. Rheumatology (Oxford) 2002;41(3):324-8
   PubMedGoogle Scholar
• Teh LS, Manning J, Moore T, et al. Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud's phenomenon. Br J Rheumatol 1995;34(7):636-41
   PubMedGoogle Scholar
• Natsuda H, Shibui Y, Yuhara T, et al. Nitroglycerin tape for Raynaud's phenomenon of rheumatic disease patients--an evaluation of skin temperature by thermography. Ryumachi 1994;34(5):849-53
   PubMedGoogle Scholar
• Kan C, Akimoto S, Abe M, et al. Preliminary thermographic evaluation of new nitroglycerine tape on the peripheral circulatory disturbance in systemic sclerosis. Ann Rheum Dis 2002;61(2):177-9
   PubMedGoogle Scholar
• Peterson LL, Vorhies C. Raynaud's syndrome: treatment with sublingual administration of nitroglycerin, swinging arm maneuver, and biofeedback training. Arch Dermatol 1983;119:396-9
   PubMedGoogle Scholar
• Chung L, Shapiro L, Fiorentino D, et al. MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial. Arthritis Rheum 2009;60(3):870-7
   PubMedGoogle Scholar
• Walker KM, Pope J. Treatment of systemic sclerosis complications: what to use when first-line treatment fails–a consensus of systemic sclerosis experts. Semin Arthritis Rheum 2012;42(1):42-55
   PubMedGoogle Scholar
• Fries R, Shariat K, von Wilmowsky H, Böhm M. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation 2005;112(19):2980-5
   PubMedGoogle Scholar
• Herrick AL, Van den Hoogen F, Gabrielli A, et al. Modified- release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis Rheum 2011;63(3):775-82
   PubMedGoogle Scholar
• Schiopu E, Hsu VM, Impens AJ, et al. Randomised placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis. J Rheumatol 2009;36(10):2264-8
   PubMed Web of Science ®Google Scholar
• Agarwal V, Ghosh P, Sharma A, et al. Efficacy of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis: a double-blind randomized placebo-controlled parallel group multicentric study [abstract]. Arthritis Rheum 2010;62(Suppl 10):2086
   PubMedGoogle Scholar
• Shenoy PD, Kumar S, Jha LK, et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology (Oxford) 2010;49(12):2420-8
   PubMed Web of Science ®Google Scholar
• Caglayan E, Huntgeburth M, Karasch T, et al. Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease. Arch Intern Med 2006;166(2):231-3
   PubMedGoogle Scholar
• Caglayan E, Axmann S, Hellmich M, et al. Vardenafil for the treatment of Raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover study. Arch Intern Med 2012;172(15):1182-4
   PubMedGoogle Scholar
• Roustit M, Blaise S, Allanore Y, et al. Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials. Ann Rheum Dis 2013;72(10):1696-9
   PubMed Web of Science ®Google Scholar
• Guiducci S, Randone SB, Bruni C, et al. Bosentan fosters microvascular de-remodelling in systemic sclerosis. Clin Rheumatol 2012;31(12):1723-5
   PubMedGoogle Scholar
• Cutolo M, Zampogna G, Vremis L, et al. Longterm effects of endothelin receptor antagonism on microvascular damage evaluated by nailfold capillaroscopic analysis in systemic sclerosis. J Rheumatol 2013;40(1):40-5
   PubMed Web of Science ®Google Scholar
• Moore TL, Vail A, Herrick AL. Assessment of digital vascular structure and function in response to bosentan in patients with systemic sclerosis-related Raynaud's phenomenon. Rheumatology (Oxford) 2007;46(2):363-4
   PubMedGoogle Scholar
• Korn JH, Mayes M, Matucci Cerinic M, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004;50(12):3985-93
   PubMed Web of Science ®Google Scholar
• Matucci-Cerinic M, Denton CP, Furst DE, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2011;70(1):32-8
   PubMed Web of Science ®Google Scholar
• Nguyen VA, Eisendle K, Gruber I, et al. Effect of the dual endothelin receptor antagonist bosentan on Raynaud's phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study. Rheumatology (Oxford) 2010;49(3):583-7
   PubMed Web of Science ®Google Scholar
• Wigley FM, Korn JH, Csuka ME, et al. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Arthritis Rheum 1998;41(4):670-7
   PubMedGoogle Scholar
• Wigley FM, Wise RA, Seibold JR, et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Ann Intern Med 1994;120(3):199-206
   PubMed Web of Science ®Google Scholar
• Belch JF, Drury J, Capell H, et al. Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome: a double-blind controlled trial. Lancet 1983;321(8320):313-15
   Google Scholar
• Seibold JR, Wigley FM, Schiopu ED, et al. Digital ischemic ulcers in scleroderma treated with oral treprostinil diethanolamine: a randomized, double-blind, placebo-controlled, multicenter study [abstract]. Arthritis Rheum 2011;63(Suppl 10):2483
   Google Scholar
• Jaffe I. Serotonin reuptake inhibitors in Raynaud's phenomenon. Lancet 1995;345(8961):1378
   PubMedGoogle Scholar
• Coleiro B, Marshall SE, Denton CP, et al. Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford) 2011;40(9):1038-43
   Google Scholar
• Surwit RS, Gilgor RS, Allen LM, et al. A double-blind study of prazosin in the treatment of Raynaud's phenomenon in scleroderma. Arch Dermatol 1984;120(3):329-31
   PubMedGoogle Scholar
• Russell IJ, Lessard JA. Prazosin treatment of Raynaud's phenomenon: a double blind single crossover study. J Rheumatol 1985;12(1):94-8
   PubMedGoogle Scholar
• Denton CP, Howell K, Stratton RJ, et al. Long-term low molecular weight heparin therapy for severe Raynaud's phenomenon: a pilot study. Clin Exp Rheumatol 1999;18(4):499-502
   Google Scholar
• Del Papa N, Cortiana M, Vitali C, et al. Simvastatin reduces endothelial activation and damage but is partially ineffective in inducing endothelial repair in systemic sclerosis. J Rheumatol 2008;35(7):1323-8
   PubMed Web of Science ®Google Scholar
• Abou-Raya A, Abou-Raya S, Helmii M. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers. J Rheumatol 2008;35(9):1801-8
   PubMedGoogle Scholar
• Sadik HY, Moore TL, Vail A, et al. Lack of effect of 8 weeks atorvastatin on microvascular endothelial function in patients with systemic sclerosis. Rheumatology (Oxford) 2010;49(5):990-6
   PubMedGoogle Scholar
• Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009;360(19):1989-2003
   PubMed Web of Science ®Google Scholar
• Sambo P, Amico D, Giacomelli R. Intravenous N-acetylcysteine for treatment of Raynaud's phenomenon secondary to systemic sclerosis: a pilot study. J Rheumatol 2001;28(10):2257-62
   PubMedGoogle Scholar
• Herrick AL, Hollis S, Schofield D, et al. A double-blind placebo-controlled trial of antioxidant therapy in limited cutaneous systemic sclerosis. Clin Exp Rheumatol 2000;18(3):349-56
   PubMedGoogle Scholar
• Stone AV, Koman LA, Callahan MF, et al. The effect of botulinum neurotoxin-A on blood flow in rats: a potential mechanism for treatment of Raynaud phenomenon. J Hand Surg Am 2012;37(4):795-802
   PubMedGoogle Scholar
• Iorio ML, Masden DL, Higgins JP. Botulinum toxin A treatment of Raynaud's phenomenon: a review. Semin Arthritis Rheum 2012;41(4):599-603
   PubMed Web of Science ®Google Scholar
• Hartzell TL, Makhni EC, Sampson C. Long-term results of periarterialsympathectomy. J Hand Surg Am 2009;34(8):1454-60
   PubMedGoogle Scholar
• Claes G, Droyt C, Göthberg G. Thoracoscopic sympathicotomy for arterial insufficiency. Eur J Surg 1994;(Suppl 572):63-4
   Google Scholar
• Raynaud M. The´se de Me´dicine: De l'asphyxie locale et de la gangre´ne des extremite´s. Lecler, Paris; 1862
   Google Scholar